Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
andecaliximab + leucovorin + 5-fluorouracil + irinotecan + bevacizumab
- Development stage
- Unknown
- Lead developer
- āshibio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a **combination regimen** consisting of five agents: \n- **Andecaliximab**: a recombinant chimeric IgG4 monoclonal antibody that selectively binds and inhibits matrix metalloproteinase-9 (MMP9), implicated in tumor progression and metastasis. \n- **Leucovorin**: a reduced folate used to modulate and enhance the cytotoxic effect of 5-fluorouracil (5-FU). \n- **5-Fluorouracil**: a pyrimidine analog antimetabolite which interferes with DNA and RNA synthesis, leading to apoptosis in rapidly dividing cells. \n- **Irinotecan**: a topoisomerase I inhibitor that causes DNA damage by preventing religation during DNA replication. \n- **Bevacizumab**: a humanized monoclonal antibody against vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and tumor blood supply. \nThis regimen has been investigated in advanced solid tumors, particularly **advanced/metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma**. The combination builds on established chemotherapy protocols (like FOLFIRI or FOLFOX) with targeted agents to inhibit both tumor cell proliferation and the supportive tumor microenvironment[1][3][7][5][2][4].
- Brand names
- None for the full five-drug combination
- Other names
- mFOLFIRI + andecaliximab + bevacizumab
02
Targets
TS (Thymidylate synthase)MMP9 (Matrix metalloproteinase-9)DHFR (Dihydrofolate reductase)TOP1 (DNA Topoisomerase I)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on andecaliximab + leucovorin + 5-fluorouracil + irinotecan + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on andecaliximab + leucovorin + 5-fluorouracil + irinotecan + bevacizumab.